Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

15:34
10/09/16
10/09
15:34
10/09/16
15:34

Merck reports long-term data from final KEYNOTE-002 analysis

Merck announced findings from the final overall survival analysis from the KEYNOTE-002 study investigating the use of Keytruda compared to investigator-choice chemotherapy with a crossover to Keytruda design, in patients with ipilimumab-refractory advanced melanoma. The results presented at the ESMO 2016 Congress include follow-up of up to 35 months for the study's co-primary endpoints of OS and progression-free survival. Data showed prolonged OS with Keytruda 2 mg/kg and 10 mg/kg, with a median OS of 13.4 months and 14.7 months and a two-year OS rate of 35.9 percent and 38.2 percent, respectively, compared to a median OS of 11.0 months and a two-year OS rate of 29.7 percent with chemotherapy. While improvements in OS between Keytruda 2 mg/kg or 10 mg/kg and chemotherapy did not meet the protocol-specified significance threshold, longer follow-up continued to show a clinically meaningful improvement in PFS, the study's co-primary endpoint, with PFS of up to 31 months in patients treated with Keytruda. Median PFS was approximately three months for each of the patient groups -- 2.8-3.8 months with Keytruda 2 mg/kg; 2.8-5.2 months with Keytruda 10 mg/kg; and 2.6-2.8 months with chemotherapy. The two-year PFS rate was 16.0 percent and 21.9 percent with Keytruda compared to 0.6 percent of patients treated with chemotherapy. ORR was 22.2 percent and 27.6 percent with Keytruda compared to 4.5 percent with chemotherapy. At the time of analysis, 50 percent and 58 percent of patients who responded to Keytruda were alive with no subsequent progression or anti-tumor therapy, compared to 12 percent of patients who responded to chemotherapy. With longer follow-up, adverse events have remained consistent with previously reported safety data.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

NTRS

Northern Trust

$96.66

1.24 (1.30%)

16:52
06/28/17
06/28
16:52
06/28/17
16:52
Hot Stocks
Northern Trust to increase dividend to 42c per share, buy back $750M in stock »

Northern Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

SBOT

Stellar Biotechnologies

$1.23

-0.05 (-3.91%)

16:51
06/28/17
06/28
16:51
06/28/17
16:51
Hot Stocks
Breaking Hot Stocks news story on Stellar Biotechnologies »

Frank R. Oakes reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$71.94

0.14 (0.19%)

16:51
06/28/17
06/28
16:51
06/28/17
16:51
Hot Stocks
Comerica plans to increase dividend 15%, buy back up to $605M of common stock »

Comerica announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$89.82

1.77 (2.01%)

16:50
06/28/17
06/28
16:50
06/28/17
16:50
Hot Stocks
JPMorgan to up quarterly dividend to 56c/share, authorizes $19.4B share buyback »

JPMorgan Chase & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

BBVA

Banco Bilbao

$8.54

0.16 (1.91%)

16:50
06/28/17
06/28
16:50
06/28/17
16:50
Hot Stocks
BBVA Compass receives no objection to its 2017 capital plan »

BBVA Compass Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ZION

Zions Bancorp

$42.97

0.43 (1.01%)

16:49
06/28/17
06/28
16:49
06/28/17
16:49
Hot Stocks
Zions to boost common dividend to 24c per share by 2Q18 »

The Board of Governors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$123.40

2.28 (1.88%)

16:48
06/28/17
06/28
16:48
06/28/17
16:48
Hot Stocks
PNC says proposed capital plans include 36% dividend hike, $2.7B in buybacks »

The PNC Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jul

MBUU

Malibu Boats

$25.75

0.28 (1.10%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
Malibu Boats to acquire Cobalt Boats for $130M »

Malibu Boats announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$48.61

0.27 (0.56%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
CIT Group receives no objection to its 2017 capital plan »

CIT Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$61.88

0.81 (1.33%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
Discover to boost quarterly dividend to 35c per share, authorizes $2.23B buyback »

Discover Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AMZN

Amazon.com

$990.33

13.55 (1.39%)

, WMT

Wal-Mart

$76.51

0.5 (0.66%)

16:46
06/28/17
06/28
16:46
06/28/17
16:46
Periodicals
Amazon holds first ever 'meet and greet' for sellers, Bloomberg says »

Amazon (AMZN) is holding…

AMZN

Amazon.com

$990.33

13.55 (1.39%)

WMT

Wal-Mart

$76.51

0.5 (0.66%)

EBAY

eBay

$35.31

0.4 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

STI

SunTrust

$56.09

0.88 (1.59%)

16:46
06/28/17
06/28
16:46
06/28/17
16:46
Hot Stocks
SunTrust boosts quarterly dividend 54%, authorizes $1.32B share buyback »

SunTrust Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

KEY

KeyCorp

$18.38

0.18 (0.99%)

16:44
06/28/17
06/28
16:44
06/28/17
16:44
Hot Stocks
KeyCorp to boost quarterly dividend to 10.5c per share, to repurchase $800M »

KeyCorp announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$50.60

0.92 (1.85%)

16:43
06/28/17
06/28
16:43
06/28/17
16:43
Hot Stocks
BNY Mellon to raise dividend 24%, repurchase up to $3.1B of common stock »

BNY Mellon announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

CFG

Citizens Financial

$35.34

0.5 (1.44%)

16:42
06/28/17
06/28
16:42
06/28/17
16:42
Hot Stocks
Citizens Financial plans 18c per share quarterly dividends, $850M share buyback »

Citizens Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

FITB

Fifth Third

$25.49

0.4 (1.59%)

, VNTV

Vantiv

$63.47

1.09 (1.75%)

16:41
06/28/17
06/28
16:41
06/28/17
16:41
Hot Stocks
Fifth Third to raise dividend to 16c, repurchase $1.161B of common stock »

Fifth Third Bancorp…

FITB

Fifth Third

$25.49

0.4 (1.59%)

VNTV

Vantiv

$63.47

1.09 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

BBT

BB&T

$44.78

0.96 (2.19%)

16:41
06/28/17
06/28
16:41
06/28/17
16:41
Hot Stocks
BB&T says proposed capital plans include 10% dividend hike, $1.88B in buybacks »

BB&T announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 19

    Oct

MBUU

Malibu Boats

$25.75

0.28 (1.10%)

16:40
06/28/17
06/28
16:40
06/28/17
16:40
Hot Stocks
Breaking Hot Stocks news story on Malibu Boats »

Malibu Boats trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$83.97

0.89 (1.07%)

16:40
06/28/17
06/28
16:40
06/28/17
16:40
Hot Stocks
American Express to increase dividend by 9%, buy back $4.4B in stock »

American Express Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

C

Citi

$65.18

0.95 (1.48%)

16:39
06/28/17
06/28
16:39
06/28/17
16:39
Hot Stocks
Citi plans 32c per share quarterly dividend, $15.6B share buyback »

The Federal Reserve Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 14

    Jul

  • 20

    Jul

  • 25

    Jul

COF

Capital One

$82.98

1.6 (1.97%)

, ALLY

Ally Financial

$21.19

0.2 (0.95%)

16:39
06/28/17
06/28
16:39
06/28/17
16:39
Hot Stocks
Fed completes CCAR review, says Capital One required to resubmit »

The Federal Reserve Board…

COF

Capital One

$82.98

1.6 (1.97%)

ALLY

Ally Financial

$21.19

0.2 (0.95%)

AXP

American Express

$83.97

0.89 (1.07%)

BAC

Bank of America

$23.88

0.61 (2.62%)

BK

BNY Mellon

$50.60

0.92 (1.85%)

BBT

BB&T

$44.78

0.96 (2.19%)

C

Citi

$65.18

0.95 (1.48%)

CFG

Citizens Financial

$35.34

0.5 (1.44%)

CMA

Comerica

$71.94

0.14 (0.19%)

DB

Deutsche Bank

$17.91

0.4 (2.28%)

DFS

Discover

$61.88

0.81 (1.33%)

FITB

Fifth Third

$25.49

0.4 (1.59%)

GS

Goldman Sachs

$223.22

2.94 (1.33%)

HSBC

HSBC

$44.65

0.54 (1.22%)

HBAN

Huntington Bancshares

$13.14

0.23 (1.78%)

JPM

JPMorgan

$89.82

1.77 (2.01%)

KEY

KeyCorp

$18.38

0.18 (0.99%)

MS

Morgan Stanley

$44.32

0.1 (0.23%)

NTRS

Northern Trust

$96.66

1.24 (1.30%)

PNC

PNC Financial

$123.40

2.28 (1.88%)

RF

Regions Financial

$14.09

0.09 (0.64%)

SAN

Banco Santander

$6.85

0.19 (2.85%)

STT

State Street

$89.66

1.76 (2.00%)

STI

SunTrust

$56.09

0.88 (1.59%)

USB

U.S. Bancorp

$51.98

0.84 (1.64%)

WFC

Wells Fargo

$54.33

1.17 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

RF

Regions Financial

$14.09

0.09 (0.64%)

16:38
06/28/17
06/28
16:38
06/28/17
16:38
Hot Stocks
Regions capital plan of $1.47B buyback, 9c per share dividend gets non-objection »

The Federal Reserve…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

USB

U.S. Bancorp

$51.98

0.84 (1.64%)

16:38
06/28/17
06/28
16:38
06/28/17
16:38
Hot Stocks
U.S. Bancorp receives no objection to its 2017 capital plan »

U.S. Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 18

    Oct

  • 17

    Jan

COF

Capital One

$82.98

1.6 (1.97%)

16:37
06/28/17
06/28
16:37
06/28/17
16:37
Hot Stocks
Capital One CCAR plan gets conditional non-objection, must resubmit capital plan »

Capital One Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 20

    Jul

STT

State Street

$89.66

1.76 (2.00%)

16:37
06/28/17
06/28
16:37
06/28/17
16:37
Hot Stocks
State Street to increase dividend to 42c and repurchase up to $1.4B in stock »

State Street announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.